Shift From Adalimumab Originator to Biosimilars in Denmark

Thomas Bo Jensen; Seoyoung C Kim; Espen Jimenez-Solem; Dorthe Bartels; Hanne Rolighed Christensen; Jon Trærup Andersen

doi:10.1001/jamainternmed.2020.0338

Shift From Adalimumab Originator to Biosimilars in Denmark

Thomas Bo Jensen, Seoyoung C Kim, Espen Jimenez-Solem, Dorthe Bartels, Hanne Rolighed Christensen, Jon Trærup Andersen

Klinisk Farmakologisk Afd.

65 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	JAMA Internal Medicine
Vol/bind	180
Udgave nummer	6
Sider (fra-til)	902-903
Antal sider	2
ISSN	2168-6106
DOI	https://doi.org/10.1001/jamainternmed.2020.0338
Status	Udgivet - 1 jun. 2020

Adgang til dokumentet

10.1001/jamainternmed.2020.0338

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{e09aca06bd00484c8732374faefec199,

title = "Shift From Adalimumab Originator to Biosimilars in Denmark",

author = "Jensen, {Thomas Bo} and Kim, {Seoyoung C} and Espen Jimenez-Solem and Dorthe Bartels and Christensen, {Hanne Rolighed} and Andersen, {Jon Tr{\ae}rup}",

year = "2020",

month = jun,

day = "1",

doi = "10.1001/jamainternmed.2020.0338",

language = "English",

volume = "180",

pages = "902--903",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Shift From Adalimumab Originator to Biosimilars in Denmark

AU - Jensen, Thomas Bo

AU - Kim, Seoyoung C

AU - Jimenez-Solem, Espen

AU - Bartels, Dorthe

AU - Christensen, Hanne Rolighed

AU - Andersen, Jon Trærup

PY - 2020/6/1

Y1 - 2020/6/1

UR - http://www.scopus.com/inward/record.url?scp=85082406163&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2020.0338

DO - 10.1001/jamainternmed.2020.0338

M3 - Letter

C2 - 32227137

SN - 2168-6106

VL - 180

SP - 902

EP - 903

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 6

ER -